1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight

Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight

  • August 2016
  • 660 pages
  • ID: 4397184
  • Format: PDF
  • Kuick Research


Table of Contents

Cancer is ever fastest growing global epidemic and one of the leading causes of death in the developed countries. It was observed that year 2015 alone witnessed more than 10 million new cancer cases. The number of new cancer cases is predicted to rise to 22 million within the next two decades. More than 60 percent of the world’s new cancer cases occur in Africa, Asia, and Central and South America; 70 percent of the world’s cancer deaths also occur in these regions. The future burden will probably be even larger because of the adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and fewer childbirths, in economically developing countries.

Owing to this, the cancer segment of pharmaceutical industry is most studied and highly competitive in nature. The chemotherapeutic products are extremely diverse ranging from monoclonal antibodies, vaccines, immunomodulators, and hormonal therapies to bispecific monoclonal antibodies including the miscellaneous drugs. All the aforementioned drugs are formulated in a way to be step ahead in targeted approach from their predecessor. Nevertheless, all the above mentioned therapies have their own limitations; either they should be given in conjunction with other therapies, require high dose or have got enormous side effects and so on. They too have different pharmacological parameters, overlapping boundaries and cost effectiveness.

One of the major segments of cancer therapy is occupied by the angiogenesis inhibitors. The market for angiogenesis inhibitors is quiet optimistic as they have emerged as the new targeted therapy for the cancer treatment. These molecules due their specificity are gaining a lot of manufacturer’s interest. With advent of new and improved technology, angiogenesis inhibitors therapy witnessed a drastic transition and is becoming more acceptable due to its site specific approach. They have become a critical component of clinical treatment procedure for a variety of indications.

Angiogenesis is an important hallmark of tumor development. Hence, targeting angiogenesis is for sure help to eradicate the cancer. Similarly, metastasis is now a validated target for cancer treatment, the overall benefits of anti-angiogenic drugs from the perspective of impacting survival have left much to desire, endorsing a need for developing more effective therapeutic regimens. The anti angiogenic drugs are being combined with established conventional chemotherapeutic drugs to produce the desirable effect. There are now several agents available in the market such as bevacizumab that target the tumor vasculature through different pathways, either by inhibiting formation of the tumor neovasculature or by directly targeting the mature tumor vessels.

Although it has been found that their effects are compounded by their synergistic use with conventional chemotherapy rather than individual agents. For instance, an antiangiogenic drug such as bevacizumab is potent enough to bring about a transient functional normalization of the tumor vasculature. So, in order to get the maximum results out of it; this can be co-administered with chemo/radiotherapy.

Therapeutic innovations in various segments have made the transition from human conception to clinical reality over the past two decades and reached from labs to bedside of the patients. Now, many of angiogenesis inhibitors are being tested as adjuvant or first-line therapies to determine their efficacy in improving survival. Although majorly angiogenesis inhibitors are used as supportive therapy rather than streamline drugs as they take huge time to even show reasonable results. The market is no doubt flourishing and is sure to increase many folds as with due acceptance of clinicians and patients due to their targeted effect.

In future, the information drawn from genome medical science and genome-informatics that clearly identifies the disease centric antigens valuable for medical treatment is being employed to develop the therapy using mAbs. Currently, the more attention is getting paid toward targeted therapy. Several angiogenesis inhibitors, alone and in combination with other conventional therapies, are being tested in phase I and phase II clinical trials at the moment. The health market in coming years is sure to get loaded with BsAbs with prior approval of these prospective drugs.

Hence, it is quiet predictable that global market for angiogenesis inhibitors for cancer treatment is expected to register a healthy annual market growth rate during the forecast period. The healthy growth rate can be related to the cumulative effects such as fast technological development, upsurge in the number of incidences of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Melanoma Drug Market Research Report by Type of Melanoma, by Therapy - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • $ 4949
  • January 2021
  • 185 pages

Melanoma Drug Market Research Report by Type of Melanoma (Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma, and Superficial Spreading Melanoma), by Therapy (Chemotherapy, Immunotherapy, ...

  • World
  • Dermatological Condition
  • Cancer
  • Industry analysis

Global Cancer Therapies Industry $ 5450 September 2020


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on